We hypothesized that ITI-1001 vaccination in our mouse GBM model would result in the generation of activated CD4 Th1 cells that in turn would result in the enhanced activation of CD8 T cytotoxic killer cells by DC licensing and cytokine release (27, 33). The gene discussed is CD8A; the disease is glioblastoma.